Gao WH, Luo H, Zhu QY, Jiang Q, Lian LX. Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study. World J Clin Oncol 2026; 17(5): 120140 [DOI: 10.5306/wjco.v17.i5.120140]
Corresponding Author of This Article
Qing-Yao Zhu, Research Dean, Department of Radiation Oncology, Henan Provincial People’s Hospital, Weiwu Road, Zhengzhou 450003, Henan Province, China. lindayue7768@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
May 24, 2026 (publication date) through May 23, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Gao WH, Luo H, Zhu QY, Jiang Q, Lian LX. Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study. World J Clin Oncol 2026; 17(5): 120140 [DOI: 10.5306/wjco.v17.i5.120140]
World J Clin Oncol. May 24, 2026; 17(5): 120140 Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.120140
Prognostic value of lung immune prognostic index in stage I non-small cell lung cancer treated with stereotactic body radiotherapy: A two-center study
Wei-Hua Gao, Hui Luo, Qing-Yao Zhu, Qiang Jiang, Li-Xia Lian
Wei-Hua Gao, Qing-Yao Zhu, Qiang Jiang, Li-Xia Lian, Department of Radiation Oncology, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan Province, China
Hui Luo, Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China
Author contributions: Gao WH and Zhu QY participated in the conception and design of the study; Gao WH, Zhu QY, Luo H, Jiang Q, and Lian LX were involved in the acquisition, analysis, or interpretation of data; Gao WH and Zhu QY wrote the manuscript; Gao WH, Zhu QY, and Luo H accessed and verified the study data; and all authors critically reviewed and approved the final manuscript to be published.
AI contribution statement: Deepseek has been used for language polishing of the manuscript (the results and discussion section). There was no Artificial Intelligence tool that participate in design of the study or interpretation of the results. All the images in the manuscript was generated by the authors themself.
Institutional review board statement: The present study was approved by the Research Ethics Committee of the Zhengzhou University People’s Hospital and Cancer Hospital.
Informed consent statement: Informed consent statement was finished prior to anticancer therapy.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Not applicable.
Corresponding author: Qing-Yao Zhu, Research Dean, Department of Radiation Oncology, Henan Provincial People’s Hospital, Weiwu Road, Zhengzhou 450003, Henan Province, China. lindayue7768@sina.com
Received: February 24, 2026 Revised: March 15, 2026 Accepted: April 10, 2026 Published online: May 24, 2026 Processing time: 93 Days and 20.5 Hours
Abstract
BACKGROUND
The lung immune prognostic index (LIPI) has been shown to correlate with prognosis in patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT).
AIM
To evaluate the utility of the pretreatment LIPI score as a supplementary prognostic marker in patient with early-stage NSCLC treated with SBRT.
METHODS
Patients with stage I NSCLC who underwent SBRT were retrospectively analyzed. Pretreatment LIPI scores were calculated based on complete blood cell counts and lactate dehydrogenase levels. Patients were stratified into two groups: Good LIPI (0 factors) and poor LIPI (1-2 factors). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and the association between LIPI score and prognosis was assessed using Cox proportional hazards regression analysis.
RESULTS
A total of 68 patients were included. LIPI scores varied across the cohort. Kaplan-Meier analysis demonstrated significantly different prognoses between the two groups (P < 0.05). Significantly longer OS and PFS were observed in patients with good LIPI scores compared to those with poor LIPI scores. Multivariate analysis identified LIPI as an independent prognostic factor for OS.
CONCLUSION
The pretreatment LIPI score represents a useful prognostic marker for patients with stage I NSCLC treated with SBRT.
Core Tip: The pretreatment lung immune prognostic index (LIPI) serves as a useful, independent prognostic marker for patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy. Based on routine blood counts and lactate dehydrogenase levels, LIPI effectively stratifies patients into distinct risk groups, with those classified as “Poor LIPI” experiencing significantly shorter median overall survival compared to those with “Good LIPI”. This readily available tool can supplement traditional evaluations to identify high-risk individuals who may benefit from closer monitoring.
